Early salvage radiotherapy following radical prostatectomy indicated in patients with rising PSA levels below the conventional threshold of biochemical recurrence 0.2 ng/ml
Published in:
Ces Urol 2012; 16(2): 92-100
Category:
Original article
Overview
Aim:
Prostate specific antigen (PSA) after radical prostatectomy (RP) assessed by ultrasensitive assay may help to detect biochemical recurrence (BR) at an early stage and thus probably more sensitive to salvage radiotherapy (SRT). We aimed to evaluate the efficacy of SRT in patients after RP with postoperative PSA increase below the levels 0.2 ng/ml and 0.2–0.3 ng/ml.
Methods:
The prospective analysis comprised 52 patients who underwent SRT for rising PSA after RP for localized prostate cancer. Rising PSA was defined as three consecutive rises of PSA measured by an ultrasensitive PSA assay (Immulite 2000 3rd Generation PSA, Siemens Medical, detection limit 0.003 ng/ml). Inclusion criteria were no history of hormonal therapy, postoperative PSA nadir lower than 0.1 ng/ml, indication for SRT with the PSA value lower than 0.2 ng/ml and a minimum follow-up after SRT 9 months. SRT was indicated in PSA levels below 0.2 ng/ml, in 11 patients SRT was started in PSA levels 0.2–0.3 ng/ml. SRT was delivered to the prostatic bed (60 Gy) followed by boost at a total dose of 72–76 Gy. SRT failure was defined as three consecutive rises of PSA after SRT measured in 3 months’ intervals.
Results:
Median follow-up after SRT was 27 months (range 9–48 months). Mean follow-up after SRT was also 27 months. SRT was in two of 52 patients (3.8%) practically without any effect. Long-term successful SRT lasting 27 months in average (9–48 months) was seen in 43 of 50 patients (86%). Repeated PSA rise was seen in seven patients after temporary PSA decline lasting 15–27 months (median 15, mean 18 months). In three of them the rise exceeded the threshold of 0.2 mg/ml. All these three patients had PSA level before the beginning of SRT above 0.2 ng/ml. The rate of SRT failure was higher in the group of SRT beginning in PSA levels 0.2–0.3 ng/ml (five of 11 patients, 45.5%) then in the group, where the SRT was started at PSA levels under 0.2 ng/ml (two of 39 patients, 5.1%, p < 0.01, Chi-square test). Median and mean PSA level in the time of SRT beginning differed signifi cantly between the group of SRT-failures (0.207 and 0.201 ng/ml) and the group of long-term successful SRT (0.133 and 0.134 ng/ml; p = 0.016, Mann-Whitney test).
Conclusions:
Results of this study indicate that early SRT in time when the patients’ PSA elevation after RP did not reach the conventional threshold of biochemical recurrence yet, may lead to objective response in terms of long-lasting absence of PSA elevation. More favorable outcomes were associated with PSA values under the value of 0.2 ng/ml at the time of SRT.
Key words:
prostate cancer, PSA recurrence, radical prostatectomy, salvage radiotherapy.
Sources
1. Odrážka K, Doležel M, Vaňásek J, Vaculíková M, Zouhar M, Šefrová J, Paluska P, Vošmik M, Kohlová T, IKolářová I, Broďák M, Navrátil P, Prošvic P, Hoff mann P, Hafuda A. Chronická urinární toxicita 3D-CRT a IMRT karcinomu prostaty. Ces Urol 2010; 14(3): 156–163.
2. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281(17): 1591–1597.
3. Ganswindt U, Stenzl A, Bamberg M, Belka C. Adjuvant radiotherapy for patients with locally advanced prostate cancer – a new standard? Eur Urol 2008; 54(3): 528–542.
4. Simon MA, Kim S, Soloway MS. Prostate specifi c antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J Urol 2006; 175(1): 140–144.
5. Lodde M, Lacombe L, Fradet Y. pT2-3N0M0 prostate cancer with positive and negative margins:clinical outcome and time to salvage radiotherapy. Eur Urol Suppl 2010; 9(2): 207–621.
6. Cozzarini C. Editorial comment on: Adjuvant radiotherapy for patients with locally advanced prostate cancer – a new standard? Eur Urol 2008; 54(3): 540–541.
7. Nohra J, Huyghe E, Soulie M, Khedis M, Rischmann P, Malavaud B, Pierre P. Late severe complications (G3-4 RTOG) of 3D conformal adjuvant radiotherapy for prostate KC after radical retropubic prostatectomy. Eur Urol Suppl 2006; 5(2): 169.
8. Da Pozzo L. Editorial comment on: Adjuvant radiotherapy for patients with locally advanced prostate cancer – a new standard? Eur Urol 2008; 54(3): 541–542.
9. Boccon-Gibod L. pT3 prostate cancer: The case for salvage (as opposed to adjuvant) radiation therapy. Eur Urol Suppl 2007; 6(8): 521–524.
10. Nudell DM, Grossfeld GD, Weinberg VK, Roach M 3rd, Carroll PR. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999; 54(6): 1049–1057.
11. D’Amico AV, Chen MH, Su L, Lee WR, Mouraviev V, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death BJU Int 2010; 106(11): 1618–1622.
12. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, DeWeese TL, Scardino PT, Stephenson AJ, Pollack A. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 2008; 72(6): 1298–1302.
13. Pacholke HD, Wajsman Z, Algood CB, Morris CG, Zlotecki RA. Postoperative adjuvant and salvage radiotherapy for prostate cancer: impact on freedom from biochemical relapse and survival. Urology 2004; 64(5): 982–986.
14. Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, Collie AC, Ferrigni RG, Myers RP, Prussak KA, Heckman MG, Crook JE, Parker AS, Igel TC. Salvage radiotherapy for isolated prostate specifi c antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006; 176(3): 985–990.
15. Loeb S, Roehl KA, Viprakasit DP, Catalona WJ. Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy. Eur Urol 2008; 54(1): 88–94.
16. Chalasani V, Iansavichene AE, Lock M and Izawa JI. Salvage radiotherapy following radical prostatectomy. Int J Urol 2009; 16(1): 31–36.
17. Cetti R, Carter P. Salvage radiotherapy after open radical retropubic prostatectomy: Our 14 year experience. Urology 2008; 72(Suppl 5A): S63.
18. Terai A, Matsui Y, Yoshimura K, Arai Y and Dodo Y. Salvage radiotherapy for biochemical recurrence after radical prostatectomy. BJU Int 2005; 96(7): 1009–1013.
19. Patel R, Lepor H, Th iel RP, and Taneja SS. Prostate-specifi c antigen velocity accurately predicts response to salvage radiotherapy in men with biochemical relapse after radical prostatectomy. Urology 2005; 65(5): 942–946.
20. Ward JF, Zincke H, Bergstralh EJ, Slezak JM and Blute ML. Prostate specifi c antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004; 172(6 Pt 1): 2244–2248.
21. Song C, Kim YS, Hong JH, Kim CS and Ahn H. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation. 2009 BJU Int 2010; 106(2): 188–193.
22. Pazona JF, Han M, Hawkins SA, Roehl KA and Catalona WJ. Salvage radiation therapy for prostate specifi c antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 2005; 174(4 Pt 1): 1282–1286.
23. Song DY, Th ompson TL, Ramakrishnan V, Harrison R, Bhavsa N, Onaodowan O and Deweese TL. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 2002; 60(2): 281–287.
24. Schild SE, Buskirk SJ, Wong WW, Halyard MY, Swanson SK, Novicki DE, Ferrigni RG. The use of radiotherapy for patients with isolated elevation of serum prostate specifi c antigen following radical prostatectomy. J Urol 1996; 156(5): 1725–1729.
25. Witjes JA, Gerrits W, Van Lin E. Salvage radiotherapy after radical prostatecromy for PSA relaps. Eur Urol Suppl 2007; 6(2): 227.
26. Chawla AK, Th akral HK, Zietman AL and Shiple WU. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of effi cacy and prognostic factors. Urology 2002; 59(5): 726–731.
27. Sandhu SS, Th ompson A, Glaiser M, Mitchel H, Brock C, Norman AJ, Parker C, Dearnaley O, Christmas T. The outcome of patients treated with salvage radiotherapy post radical prostatectomy. Eur Urol Suppl 2005; 4(3): 81.
28. Liauw SL, Webster WS, Pistenmaa DA, Roehrborn CG. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology 2003; 61(6): 1204 – 1210.
Labels
Paediatric urologist Nephrology UrologyArticle was published in
Czech Urology
2012 Issue 2
Most read in this issue
- Early salvage radiotherapy following radical prostatectomy indicated in patients with rising PSA levels below the conventional threshold of biochemical recurrence 0.2 ng/ml
- Possibilities of endoscopic management of retained incrusted ureteral stents
- Intestinal metaplasia of bladder mucosa in combination with Peutz Jeghers syndrome
- Failure of local treatment of prostate cancer